NCT01729819已完成2 期
A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 24
- 主要终点
- Change in Mean Number of Nocturnal Voids From Baseline
研究概览
简要总结
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent prior to performance of any trial-related activity
- •Female sex, at least 18 years of age (at the time of written consent)
- •Nocturia and overactive bladder symptoms present for ≥6 months prior to trial entry (patient-reported)
- •At least 2 nocturnal voids each night as documented in 2 diary periods during the screening. A mean of at least 8 daytime voids per day over 3 days with a minimum of at least 6 daytime voids each day as documented in 2 diary periods during the screening. At least 1 urgency episode each 24 hours as documented in 2 diary periods during the screening. Each diary period consists of 3 consecutive days, with at least 14 days between each period.
排除标准
- •Evidence of severe voiding dysfunction defined as:
- •More than 10 nocturnal voids per 24 hours as documented on any of the days in both diary periods during screening.
- •More than 20 daytime voids per 24 hours as documented on any of the days in both diary periods during screening.
- •Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder related pain, or stone in the bladder and urethra causing symptoms
- •Current or a history within 5 years of lower urologic malignancies (e.g., bladder cancer), lower urinary tract surgery, previous pelvic irradiation, or severe neurological disease affecting bladder function or muscle strength (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury, spina bifida)
- •Symptoms of severe stress urinary incontinence in the opinion of the investigator
- •Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention
- •Habitual or psychogenic polydipsia (fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours) or a mean volume voided per void of 350 mL or more during one or more 24-hour periods as assessed by the screening diaries
- •Central or nephrogenic diabetes insipidus
- •Syndrome of inappropriate antidiuretic hormone (SIADH)
- •Gastric retention
- •Myasthenia gravis
- •Uncontrolled narrow-angle glaucoma
- •Suspicion or evidence of cardiac failure
- •Uncontrolled and clinically relevant (in the judgement of the investigator) hypertension or diabetes mellitus
- •History and/or current treatment of obstructive sleep apnoea
- •Hyponatraemia:Serum sodium level must not be below 135 mmol/L
- •Evidence of potential renal impairment:Serum creatinine must be within normal laboratory reference intervals AND estimated glomerular filtration rate must be more than or equal to 50 mL/min
- •Hepatic and/or biliary diseases: Aspartate aminotransferase and/or alanine aminotransferase levels must not be more than twice the upper limit of normal range. Total bilirubin level must not be more than 1.5 mg/dL
- •Pregnancy, breastfeeding, or a plan to become pregnant during the period of the trial. Women of reproductive age must have documentation of a reliable method of contraception. All pre- and perimenopausal women have to perform pregnancy tests. Amenorrhea of more than 12 months duration based on the reported date of the last menstrual period is sufficient documentation of post-menopausal status and does not require a pregnancy test
- •Known alcohol or substance abuse; work or lifestyle that may interfere with regular night-time sleep e.g., shift workers; or any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, illiteracy or language barrier which, in the judgement of the investigator, would impair participation in the trial
- •Known or suspected hypersensitivity to any active ingredient or excipients in the investigational medicinal products used in the trial
- •Previous participation in any desmopressin trial within the last 5 years
- •Use of any prohibited therapy, as defined in the protocol
研究组 & 干预措施
Tolterodine
Active Comparator
Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
干预措施: Placebo orally disintegrating tablets (Drug)
Combination
Experimental
Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
干预措施: Tolterodine tartrate extended release capsules (Drug)
Combination
Experimental
Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
干预措施: Desmopressin orally disintegrating tablets (Drug)
Tolterodine
Active Comparator
Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
干预措施: Tolterodine tartrate extended release capsules (Drug)
结局指标
主要结局
Change in Mean Number of Nocturnal Voids From Baseline
时间窗: Baseline to 3 months of treatment
A nocturnal void was defined as a void occurring at least 5 minutes after going to bed, but before getting up the next morning. The mean estimate was the average over 3 consecutive 24-hour periods prior to the respective visit as captured in the voiding and sleep diary.
次要结局
- Change in Mean Time to First Nocturnal Void From Baseline(Baseline to 3 months of treatment)
- Change in the Impact on Sleep as Measured by the Sleep Rating Scales From Baseline(Baseline to 3 months of treatment)
- Change in Mean Nocturnal Urine Volume From Baseline(Baseline to 3 months of treatment)
- Responder Status(Baseline to 3 months of treatment)
- Onset of Effect as Seen in Change in Mean Number of Nocturnal Voids From Baseline for Each Visit During Three Months of Treatment(Baseline to 3 months of treatment)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
3 期
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female SubjectsNocturiaNCT02905682Ferring Pharmaceuticals190
已完成
3 期
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male SubjectsNocturiaNCT02904759Ferring Pharmaceuticals342
已完成
4 期
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet ObstructionUrinary IncontinenceNCT00147654Pfizer's Upjohn has merged with Mylan to form Viatris Inc.830
已完成
3 期
Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male PatientsNocturiaNCT01262456Ferring Pharmaceuticals395
已完成
3 期
A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute MigraineMigraineNCT00300924Diamond Headache Clinic200